|
Attention Physicians
and Health Care Providers
Promote
Health With Evidenced Based Wellness
|
If you would like to carry SeaLogix ® Fish Oil
in your office, please call 888-895-9668 and we’ll be happy
to make arrangements for you. You can also
email us
with your request. Be sure to include your name, phone
number, time zone and the best time to reach you. (Your
information will remain confidential.) We have
special pricing and a FREE Affiliate Program for
health care professionals!
So contact us today!
 If
you're interested in receiving "The OmegaZone Dietary
Program and Eicosanoid Modulation" booklet, let us know as
well! This brochure is for physicians and health
care providers only,
and is a formal document by Dr. Barry Sears
describing the role of eicosanoids and wellness.
For an
information sheet to share with clients about where they can
purchase the ultra refined fish oil,
Click Here Now.
(If you do not have Adobe
Reader installed you can download it from the link below.)
Get Adobe Reader
SeaLogix® References
|
|
Frequently
Asked Questions and Refences
about Ultra Refined SeaLogix®
Fish Oil
What are Omega-3 fatty acids?
Omega-3’s belong to a group of fatty acids
known as long-chain polyunsaturated fatty
acids. Because the body does not manufacture
them, Omega-3's are classified as "essential
fatty acids" (EFA’s), as it is essential
they be obtained from food. There are three
important Omega-3 fatty acids: alpha-linolenic
acid (ALA), eicosapentaenoic acid (EPA), and
docosahexaenoic acid (DHA). EPA and DHA are
found in fish, while ALA is found only in
plant foods such as flaxseed meal. The body
can convert ALA into small amounts of EPA
and DHA, but recent studies have indicated
that our bodies are somewhat inefficient in
this conversion. Therefore, it is necessary
to supplement your diet with these nutrients
in order to significantly change your levels
of Omega-3’s.
What do Omega-3 fatty acids do
for the body?
The Omega-3’s EPA and DHA are recognized for
their health benefits in all life stages.
They are important building blocks for every
cell in your body, which requires these
crucial components to grow, develop and
maintain health.* These fatty acids are an
integral part of cell membranes and are
precursors of several important cellular
messengers.* Studies have demonstrated that
EPA is important for optimal brain function
and contributes to the reduction of cellular
inflammation.* DHA has been recognized for
brain, visual and nervous system health and
development.* Additionally, these essential
fatty acids work together to contribute to
good heart health.*
What is the richest source of
Omega-3 fatty acids?
Fish oil is the richest source
for eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA). Cold-water fish,
like anchovies, salmon, sardines, tuna and
herring, are considered the best source for
these essential fatty acids. It is
important to remember, that all omega-3's
are not created equal. You would need
almost four tablespoons of flaxseed oil to
get the same amount of EPA and DHA found in
one teaspoon of Sealogix! That's
approximately ten times as much flaxseed oil
than fish oil.
Why should I take a fish oil
supplement?
Changes in food preferences and the impact
of modern food processing in Western society
have led to a significant decrease in
average dietary intake of Omega-3 fatty
acids. As a result, most American diets
contain far more Omega-6’s than Omega-3’s.
In fact, it is estimated that the average
American has between twenty to fifty times
the amount of Omega-6’s as they do
Omega-3’s. Recent studies have indicated
that this kind of imbalance can set the
stage for a host of health problems. To
promote a healthier fatty acid ratio, it is
advisable to avoid Omega-6’s (which are
commonly found in fried foods, commercial
baked goods and some margarines), and eat
more baked or broiled seafood and supplement
the diet with a high-quality fish oil like
Sealogix.
What are the health benefits
associated with taking Omega-3 EFA’s from
fish oil?
Scientific evidence has indicated that a
diet rich in Omega-3 essential fatty acids
helps support:
- A Healthy Brain
- A Healthy Heart
- A Healthy immune
system
- Healthy joint
movement
- Healthy kidneys
- A balanced mood and
sense of wellbeing
- Strength and stamina
- And helps maintain
cholesterol levels that are already
within the normal range*
|
We
invite you to review our extensive research
section, which provides summaries of recent
scientific inquiries into the health
benefits of omega-3 fatty acids from fish
oil.
Why does purity matter with
regard to fish oil?
Unfortunately, pollution has affected the
water quality of all of our oceans. The
contaminants in our waters include toxins
like mercury, PCB’s, arsenic, lead and
cadmium. Consequently, many fish now contain
these undesirable elements. That is why it
is very important to choose a fish oil that
is molecularly distilled. Molecular
distillation is a process that concentrates
and purifies the fish oil, removing the
contaminants. It is also important to select
a fish oil product that is tested for
concentration, toxicity and safety by an
independent third party. Supplementing your
diet with a pharmaceutical-grade fish oil
like Sealogix allows you to get the
additional Omega-3 fatty acids you need
without worrying about the presence of
harmful levels of pollutants.
I’ve researched many fish oil
supplements. What makes Sealogix better?
Sealogix is an ultra-refined,
ultra-concentrated, pharmaceutical-grade
fish oil awarded an IFOS 5-Star rating for
purity and concentration. Because Sealogix
is ultra-refined, you can feel confident you
are ingesting one of the purest fish oils
available. And because Sealogix is
ultra-concentrated, you receive more Omega-3
fatty acids EPA and DHA for your money. We
invite you to compare Sealogix to other
popular brands of fish oil currently on the
market. We think you’ll agree that our
product represents an exceptional value.
What is IFOS and what does a
“5-Star Rating” mean?
IFOS (International Fish Oil Standards) is a
division of Nutrasource Diagnostics, Inc.,
that provides independent, third-party
testing for our Sealogix
Omega-3 Pharmaceutical-Grade Fish Oil
products. IFOS testing judges the quality,
purity and concentration of fish oil, based
upon the international standards established
by the World Health Organization and the
Council for Responsible Nutrition. Our
rating lets you know that Sealogix is of the
highest quality available on the market
today – there is no better rating than a
5-Star.
Do you guarantee freshness and
purity?
Yes. When you order Sealogix, we promise to
deliver the highest-quality products in
excellent condition, right to your front
door. If for any reason your purchase does
not meet with your satisfaction, we will
gladly replace the product or refund your
money (excluding delivery charges). For
detailed information on our return policy,
please see the invoice included in your
shipment.
How much Sealogix should I take?
The suggested serving for a healthy adult is
four Sealogix capsules daily or one teaspoon
of Sealogix liquid supplement daily. Always
consult your health care provider for
additional guidance on how Omega-3 fatty
acids from fish oil can benefit your
personal health profile.
What’s the best way to store
Sealogix?
Store Sealogix capsules in a cool, dry place
between 58 and 75 degrees Fahrenheit to
maintain maximum freshness.
Store Sealogix liquid in the freezer or
refrigerator after opening.
I’ve heard that some fish oils
don’t taste very good. What does the liquid
Sealogix taste like?
Sealogix liquid fish oil is
virtually tasteless and has a slight citrus
flavor.
|
|
|
*These statements have not
been evaluated by the Food and Drug
Administration. This product is not intended
to diagnose, treat, cure or prevent any
disease. |
|
 |
|
SeaLogix ®
References:
|
Scientific Evidence Reveals a Diet Rich
in
Long-chain Omega-3 Fatty Acids Helps
Support:
|
|
A Healthy Brain*
A Healthy Heart*
A Healthy Immune System*
Healthy Joint Movement* |
Healthy Kidneys*
Balanced Mood and Sense of Well
Being*
Strength and Stamina*
And Helps Maintain Cholesterol Levels
that are Already within the Normal Range* |
|
Helps
Support A Healthy Brain
|
Burgress, J. R., L. Stevens, and L.
Peck. "Long-chain polyunsaturated fatty
acids in children with attention-deficit
hyperactivity disorder." Am J Clin
Nutr 71:327S-330S (2000).
Connor, W. E., M. Neuringer, and D. S.
Lin. "Dietary effects on brain fatty
acid composition: The reversibility of
n-3 fatty acids deficiency and turnover
of docosahexaenoic acid in the brain
erythrocytes and plasma of rhesus
monkeys." J Lipid Res 31:237-247
(1990).
Connor, W. E., M. Neuringer, and S.
Reisbick. "Essential fatty acids:
Importance of n-3 fatty acids in the
retina and brain." Ntr Rev
50:21-29 (1992).
Conquer, J. A., M. C. Tierney, J.
Zecevic, W.J. Bettger, and R.H. Fisher.
"Fatty acid analysis of blood plasma of
patients with Alzheimer's disease, other
types of dementia, and cognitive
impairment." Lipids 35:1305-1312
(2000).
Fenton W. ., Dickerson F., Boronow J.,
Hibbeln J. R., Knable M. “A
placebo-controlled trial of omega-3
fatty acid (ethyl eicosapentaenoic acid)
supplementation for residual symptoms
and cognitive impairment in
schizophrenia.” Am J Psychiatry
158(12):2071-4 (2001).
Gamoh, S., M. Hashimoto, K. Sugioka, S.
Hossain, N. Hata, Y. Misawa, and S.
Masumura. "Chronic administration of
docosahexaenoic acid improves reference
memory-related learning ability in young
rats." Neurosci 93:237-241
(1999).
Jones, C. R., T. Aria, and S. I.
Rapoport. "Evidence for the involvement
of docosahexaenoic acid in cholinergic
simulated signal transduction at the
synapse." J Neurochem Res
22:663-670 (1997).
Katzman, R., and J. E. Jackson.
"Alzheimer disease: Basic and clinical
advances." J Am Geriatrics Soc
39:516-525 (1991).
Kodas E., Page G., Zimmer L., Vancassel
S., Guilloteau D., Durand G., Chalon S.
"Neither the density nor function of
striatal dopamine transporters were
influenced by chronic n-3
polyunsaturated fatty acid deficiency in
rodents.” Neurosci Lett
321(1-2):95-9 (2002).
Kyle, D. J., E. Schaefer, G. Patton, and
A. Beiser. "Low serum docosahexaenoic
acid is a significant risk factor for
Alzheimer's dementia." Lipids
34:S245 (1999).
Lauritzen, I., N. Blondeau, C. Heurteaux,
C. Widmann, G. Romey, and M. Lazdunski.
"Polyunsaturated fatty acids are potent
neuroprotectors." EMBO J
19:1784-1793 (2000).
Lauritzen, L., H. S. Hansen, M. H.
Jorgensen, and K. F. Michaelsen. "The
essentiality of long-chain n-3 fatty
acids in relation to development and
function of the brain and retina."
Prog Lipid Res 40:1-94 (2001).
Marangell L B, Martinez J M, Zboyan H A,
Kertz B, Kim H F, Puryear L J. “A
double-blind, placebo-controlled study
of the omega-3 fatty acid
docosahexaenoic acid in the treatment of
major depression.” Mood Disorders
Center, Department of Psychiatry, Baylor
College of Medicine, Houston, TX, USA.
Schiefermeier M., Yavin E. “n-3
Deficient and docosahexaenoic
acid-enriched diets during
critical periods of the
developing prenatal rat brain.”
J Lipid Res 43(1):124-31
(2002).
Sonderberg, M., C. Edlund, K.
Kristensson, and G. Dallner.
"Fatty acid composition of brain
phospholipids in aging and
Alzheimer's disease." Lipids
26:421-423 (1991).
Stevens, L. J., and J. Burgess.
"Omega-3 fatty acids in boys
with behavior, learning, and
health problems." Physiol
Behav 59:915-920 (1996).
Stevens, L. J., S. S. Zentall,
J. L. Deck, M. L. Abate, B. A.
Watkins, S. A. Lipp, and J. R.
Burgess. "Essential fatty acid
metabolism in boys with
attention-deficit hyperactivity
disorder." Am J Clin Nutr
62:761-768 (1995).
Stordy, B. J. "Benefit of
docosahexaenoic acid supplements
to dark adaption in dyslexics."
Lancet 346:385 (1995).
Terano, T., S. Fujishiro, T.
Ban, K. Yamamoto, T. Tanaka, Y.
Noguchi, Y. Tamura, K. Yazawa,
and T. Hirayama. "Docosahexaenoic
acid supplementation improves
moderately severe dementia from
thromboitc cerebrovascular
diseases. Lipids
34:S345-S346 (1999).
Voigt, R. G., A. M. Llorente, C.
L. Jensen, J. K. Fraley, M.C.
Berretta, and W. C. Heird. "A
randomized, double-blind,
placebo-controlled trial of
docosahexaenoic acid
supplementation in children with
attention-deficit/hyperactivity
disorder." J Pediatr
139:189-196 (2001).
Vance, H. E., R. B. Campenot,
and D. E. Vance. "The synthesis
and transport of lipids for
axonal growth and nerve
regeneration." Biochim
Biophys Acta 1486:84-96
(2000).
Yeh, Y. Y., M. F. Gehman, and S.
M. Yeh. "Maternal dietary fish
oil enriches docosahexaenoate
levels in brain subcellular
fractions of offspring." J
Neurosci Res 35:218-226
(1993).
Yehuda, S., S. Rabinovitz, R.L.
Carasso, and D.I. Mostofsky.
"Essential fatty acid
preparation improves Alzheimer's
patients' quality of life."
Int J Neurosci 87:141-149
(1996).
Willatts, P., J. S. Forsyth, M.
K. DiModugno, S. Varma, and M.
Colvin. “Effect of long-chain
polyunsaturated fatty acids in
infant formula on problem
solving at 10 months of age.”
Lancet 352:688-691 (1998).
|
|
Helps Support A
Healthy Heart |
Albert, C. M., C. H. Hennekens, C.I.
O'Donnel, U. A. Ajani, V. J. Carey, and
W. C. Willett. "Fish consumption and
risk of sudden cardiac death." JAMA
279:23-28 (1998).
Angerer P., Kothny W., Stork S., von
Schacky C. “Effect of dietary
supplementation with omega-3 fatty acids
on progression of atherosclerosis in
carotid arteries.” Klinikum der
Universitat Munchen, Institut und
Poliklinik fur Arbeits- und
Umweltmedizin-Innenstadt,
Ziemssenstrasse 1, Germany.
Appel, Lawrence J., et al. “Does
supplementation of diet with "fish oil"
reduce blood pressure?” Archives of
Internal Medicine 153:1429-38
(1993).
Christensen, J. H., M. S. Christensen,
J. Dyerberg, and E. B. Schmidt. "Heart
rate variability and fatty acid content
of blood cell membranes: A dose-response
study with n-3 fatty acids." Am J
Clin Nutr 70:331-337 (1999).
Christensen, Jeppe Hagstrup, et al.
“Heart rate variability and fatty acid
content of blood cell membranes: a
dose-response study with n-3 fatty
acids. “ American Journal of Clinical
Nutrition 70:331-37 (1999).
Christensen, Jeppe Hagstrup, et al.
“Effect of fish oil on heart rate
variability in survivors of myocardial
infarction. “ British Medical Journal
312:677-78 (1996).
Christensen, Jeppe Hagstrup, et al.
“Heart rate variability and fatty acid
content of blood cell membranes: a
dose-response study with n-3 fatty
acids. “ American Journal of Clinical
Nutrition 70:331-37 (1999).
Dehmer, G. J., J. J. Popma, E. K. van
den Berg, E. J. Eichorn, J. B. Prewitt,
W. B. Campbell, L. Jennings, J. T.
Willerson, and J. M. Schmitz. "reduction
in the rate of early restenosis after
coronary angioplasty by a diet
supplemented with n-3 fatty acids." N
Engl J Med 319:733-740 (1998).
Engler M. M., Engler M. B., Pierson D.
M., Molteni L. B., Molteni A. “Effects
of docosahexaenoic acid on vascular
pathology and reactivity in
hypertension.” Laboratory of
Cardiovascular Physiology, Department of
Physiological Nursing, University of
California, San Francisco, California
94143-0610, USA.
Eritsland, J., H. Arnesen, K. Bronseth,
N. B. Fjeld, and M. Abdelnoor. "Effect
of dietary supplementation with n-3
fatty acids on coronary artery bypass
graft patency." Am J Cardio
77:31-36 (1996).
Eritsland, J., et al. "Long-term effects
of n-3 polyunsaturated fatty acids on
haemostatic variables and bleeding
episodes in patients with coronary
artery disease." Blood Coagulation
and Fibrinolysis 6:17-22 (1995).
Flaten, Hugo, et al. “Fish-oil
concentrate: effects of variables
related to cardiovascular disease.“
American Journal of Clinical Nutrition
52:300-06 (1990).
Geelen A., Brouwer I. A., Zock P. L.,
Kors J. A., Swenne C. A., Katan M. B.,
Schouten E. G. “(N-3) fatty acids do not
affect electrocardiographic
characteristics of healthy men and
women. J Nutr 132(10):3051-4
(2002).
GISSI-Prevenzione Investigators.
"Dietary supplementation with n-3
polyunsaturated fatty acids and vitamin
E after myocardial infarction: Results
of the GISSI-Prevenzione trial."
Lancet 354:447-455 (1999).
Harris, W. S., and W. L. Isley.
"Clinical trial evidence for the
cardioprotective effects of omega-3
fatty acids." Curr Atheroscler Rep
3:174-197 (2001).
Leaf, A., G. E. Billman, and H. Hallaq.
"Prevention of ischemia-induced
ventricular fibrillation by omega-3
fatty acids." Proc Nat Acad Sci USA
91:4427-4430 (1994).
Leaf, A., and J. X. Kang. "Dietary n-3
fatty acids in the prevention of lethal
cardiac arrhythmias." Curr Opin
Lipidol 8:4-6 (1997).
Leaf, A., J. X. Kang, Y F. Xiao, and G.
E. Billman. "Dietary n-3 fatty acids in
the prevention of cardiac arrhythmias."
Curr Opin Clin Nutr Metab Care
1:225-228 (1998).
Marchioli, Roberto, et al. “Efficacy of
n-3 polyunsaturated fatty acids after
myocardial infarction: results of
GISSI-Prevenzione trial. “ Lipids
36:S119-S126 (2001).
Marchioli, Roberto, et al. “Early
protection against sudden death by n-3
polyunsaturated fatty acids after
myocardial infarction: time-course
analysis of the results of
GISSI-Prevenzione. “ Circulation
105:1897-1903 (2002).
Morris, Martha Clare, et al. “Does fish
oil lower blood pressure? A
meta-analysis of controlled trials.“
Circulation 88(2):523-33 (1993).
Olszewski, A. J. "Fish oil decreases
homocysteine in hyperlipidemic men."
Coronary Artery Dis 4:53-60 (1993).
Radack, K. C. Deck, and G. Huster.
"Dietary supplementation with low-dose
fish oils lowers fibrinogen levels."
Ann Intern Med 11:757-758 (1989).
Radack, Kenneth, et al. “The effects of
low doses of n-3 fatty acid
supplementation on blood pressure in
hypertensive subjects. “ Archives of
Internal Medicine 151:1173-80
(1991).
Rissanen, T. S. Voutilainen, K.
Myyssonen, T.A. Lakka, and J. T. Salonen.
"Fish oil-derived fatty acids,
dodosahexaenoic acid, and
docosapentaenoic acid, and the risk of
acute coronary events: The Kuopio
ischaemic heart disease risk factor
study." Circulation 102:2677-2679
(2000).
Singh, Ram B., et al. Randomized,
double-blind, placebo-controlled trial
of fish oil and mustard oil in patients
with suspected acute myocardial
infarction: the Indian experiment of
infarct survival. Cardiovascular
Drugs and Therapy 11:485-91 (1997).
Von Schacky, C., P. Angerer, W. Kothny,
K. Theisen, and H. Mudra. "The effect of
dietary omega-3 fatty acids on coronary
atherosclerosis: A randomized,
double-blind placebo-controlled trial."
Ann Intern Med 130:554-562
(1999).
von Schacky, Clemens. n-3 fatty acids
and the prevention of coronary
atherosclerosis. American Journal of
Clinical Nutrition
71(suppl):S224-27S (2000).
|
|
Helps
Support A Healthy Immune System
|
Anti, Marcello, et al. “Effects of
different doses of fish oil on rectal
cell proliferation in patients with
sporadic colonic adenomas.”
Gastroenterology 107:1709-1718
(1994).
Barber, M. D., J. A. Ross, A. C. Voss,
M. J. Tisdale, and K. C. Fearon. "The
effect of an oral nutritional supplement
enriched with fish oil on weight-loss in
patients with pancreatic cancer.” Br
J Cancer 81:80-86 (1999).
Barber, M. D., D. C. McMillan, T.
Preston, J. A. Ross, and D. C. Fearon.
"Metabolic response to feeding in
weight-losing pancreatic cancer patients
and its modulation by a
fish-oil-enriched nutritional
supplement." Clin Sci 98:389-399
(2000).
Barber, M. D., and K. C. H. Fearon.
"Tolerance and incorporation of a
high-dose eicosapentaenoic acid diester
emulsion by patients with pancreatic
cancer cachexia." Lipids
36:347-351 (2001).l
Bechoua, S., M. Dubois, G. Nemoz, P.
Chapy, E. Vericel, M. Lagarde, and A. F.
Prigent. "Very low dietary intake of n-3
fatty acids affects the immune function
of healthy elderly people." Lipids
34:S143 (1999).
Endres, S., R. Ghorbani, V. E. Kelley,
K. Georgilis, G. Lonnemann, J. W. van
der Meer, J. G. Cannon, T. S. Rogers, M.
S. Klempner, P. C. Weber, et al. "The
effect of dietary supplementation with
n-3 polyunsaturated fatty acids on the
synthesis of interleukin-1 and tumor
necrosis factor by mononuclear cells."
N Engl J Med 320:265-271 (1989).
Ergas D., Eilat E., Mendlovic S.,
Sthoeger Z. M. “n-3 fatty acids and the
immune system in autoimmunity.” Isr
Med Assoc J 4(1):34-8 (2002).
Fernandez, E., L. Chatenoud, C. La
Vecchia, E. Negri, S. Franceschi. "Fish
consumption and cancer risk." Am J
Clin Nutr 70:85-90 (1999).
Gogos, C. A., P. Ginopoulos, B. Salsa,
E. Apostolidou, N. C. Zoumbos, and F.
Kalfarentzos. "Dietary omega-3
polyunsaturated fatty acids plus vitamin
E restore immunodeficiency and prolong
survival for severely ill patients with
generalized malignancy: A randomized
control trial." Cancer 82:395-402
(1998).
Lee, T. H., R. L. Hoover, J. D.
Williams, R. I. Sperling, J. Ravalese,
B. W. Spur, D. R. Robinson, E. J. Corey,
R. A. Lewis, and K. P Austen. "Effect of
dietary enrichment with eicosapentaenoic
acid and docosahexaenoic acid on in
vitro neurophil and monocyte leukotriene
generation and neurophil function." N
Engl J Med 312:1217-1224 (1985).
Robinson, D. R. "Alleviation of
autoimmune disease by dietary lipids
containing omega-3 fatty acids."
Rheum Dis Clin North Am 17:213-222
(1991).
Robinson, D. R., L. L. Xu, S. Tateno, M.
Guo, and R. E. Colvin. "Suppression of
autoimmune disease by dietary n-3 fatty
acids." J Lipid Res 34:1435-1444
(1993).
Sperling, R. I. "The effects of dietary
n-3 polyunsaturated fatty acids on
neutrophils." Proc Nutr Soc
57:527-534 (1998).
Terada S., Takizawa M., Yamamoto S.,
Ezaki O., Itakura H., Akagawa K. S.
Suppressive mechanisms of EPA on human T
cell proliferation.” Microbiol
Immunol 45(6):473-81 (2001).
Wigmore, S. J. M. D. Barber, J. A. Ross,
M. J. Tisdale, and K. C. Fearon. "Effect
of oral eicosapentaenoic acid on weight
loss in patients with pancreatic
cancer." Nutr Cancer 36:177-814
(2000).
|
|
Helps
Maintain Cholesterol Levels That Are
Already Within The Normal Range
|
Caron M. F., White C. M. “Evaluation of
the antihyperlipidemic properties of
dietary supplements.” Pharmacotherapy
21(4):481-7 (2001)..
Haglund, O., R. Wallin, R. Luostarinen,
and T. Saldeen. "Effects of a new fluid
fish oil concentration on triglycerides,
cholesterol, fibrinogen, and blood
pressure." J Intern Med
227:347-353 (1990).
Harris, W. S. "N-3 fatty acids and serum
lipoproteins: Human studies." Am J
Clin Nutr 65:1645S-1654S (1997).
Harris, W. S. "N-3 Fatty acids and human
lioprotein metabolism: An update."
Lipids 34:S257-S258 (1999).
Harris, W.S., H. N. Ginsberg, N.
Arunakul, N. S. Shachter, S. L. Windsor,
M. Adams, L. Berlund, and K. Osmundsen.
"Safety and efficacy of Omacor in severe
hypertriglyceridemia." J Cardiovasc
Risk 4:385-392 (1997).
Lichtenstein A. H , Ausman L. M.,
Jalbert S. M., Vilella-Bach M.,
Jauhiainen M., McGladdery S., Erkkila A.
T., Ehnholm C., Frohlich J., Schaefer E.
J. “Efficacy of a Therapeutic Lifestyle
Change/Step 2 diet in moderately
hypercholesterolemic middle-aged and
elderly female and male subjects.” J
Lipid Res 43(2):264-73 (2002).
Nilsen D. W., Albrektsen G., Landmark
K., Moen S., Aarsland T., Woie L.
“Effects of a high-dose concentrate of
n-3 fatty acids or corn oil introduced
early after an acute myocardial
infarction on serum triacylglycerol and
HDL cholesterol.” Am J Clin Nutr
74(1):50-6 (2001).
Puiggros C., Chacon P., Armadans L. I.,
Clapes J., Planas M. Effects of
oleic-rich and omega-3-rich diets on
serum lipid pattern and lipid oxidation
in mildly hypercholesterolemic patients.
Clin Nutr 21(1):79-87 (2002).
Stark, K. D., E. J. Park, V. A. Maines,
and B. J. Holub. "Effect of a fish-oil
concentrate on serum lipids in
postmenopausal women receiving and not
receiving hormone replacement therapy in
a placebo-controlled, double-blind
trial." Am J Clin Nutr 72:389-394
(2000).
Villa B., Calabresi L., Chiesa G., Rise
P., Galli C., Sirtori C. R. “Omega-3
fatty acid ethyl esters increase heart
rate variability in patients with
coronary disease. “ Department of
Pharmacological Sciences, Centre E.
Grossi Paoletti, University of Milan,
Via Balzaretti 9, 20133 Milan, Italy.
|
|
Helps
Support Healthy Joint Movement
|
Ariza-Ariza, R., M. Peralta-Mestanza,
and M. H. Cardiel. "Omega-3 fatty acids
in rheumatoid arthritis: An overview."
Sem Arthr Rheum 27:366-370
(1998).
Cleland, L. G., J. K. French, W. H.
Betts, G. A. Murphy, and M. J. Elliott.
"Clinical and biochemical effects of
dietary fish oil supplements in
rheumatoid arthritis." J Rheumatol
15:1471-1475 (1988).
Curtis C. L., Rees S. G., Cramp J.,
Flannery C. R., Hughes C. E., Little C.
B., Williams R., Wilson C., Dent C. M.,
Harwood J. L., Caterson B. “Effects of
n-3 fatty acids on cartilage
metabolism.” Proc Nutr Soc
61(3):381-9 (2002).
Espersen, G. T., N. Grunnet, H. H.
Lervang, G. L. Nielsen, B. S. Thomsen,
K. L. Faarvang, J. Dyerberg, and E.
Ernst. "Decreased interleukin-1 beta
levels in plasma from rheumatoid
arthritis patients after dietary
supplementation with n-3 polyunsaturated
fatty acids." Clin Rheumatol
11:393-395 (1992).
Fortin, Paul R., et al. “Validation of a
meta-analysis: the effects of fish oil
in rheumatoid arthritis. “ Journal of
Clinical Epidemiology 48:1379-90
(1995).
Geusens, P., C. Wouters, J. Nijs, Y.
Jiang, and J. Dequeker. "Long-term
effect of omega-3 fatty acid
supplementation in active rheumatoid
arthritis: A 12-month, double-blind,
controlled study." Arthritis Rheum
37:824-829 (1994).
Judex S., Wohl G. R., Wolff R. B., Leng
W., Gillis A. M., Zernicke R. F.
“Dietary fish oil supplementation
adversely affects cortical bone
morphology and biomechanics in growing
rabbits.” Calcif Tissue Int
66(6):443-8 (2000).
Kremer, J. M., D. A. Lawrence, W. Jubiz,
R. DiGiacomo, R. Rynes, L. F.
Bartholomew, and M. Sherman. "Dietary
fish oil and olive oil supplementation
in patients with rheumatoid arthritis:
Clinical and immunologic effects."
Arthritis Rheum 33:810-820 (1990).
Kremer, J. M., D. A. Lawrence, G. F.
Petrillo, L. L. Litts, P. M. Mullaly, R.
J. Rynes, R. P. Stocker, N. Parhami, N.
S. Greenstein, and B. R. Fuchs. "Effects
of high-dose fish oil on rheumatoid
arthritis after stopping nonsteroidal
anti-inflammatory drugs: Clinical and
immune correslates." Arthritis Rheum
38:1107-1114 (1995).
Kremer, J. M. "N-3 Fatty acid
supplements in rheumatoid arthritis."
Am J Clin Nutr 71:349S-351S (2000).
Kremer, Joel M., et al. “Fish-oil fatty
acid supplementation in active
rheumatoid arthritis: A double-blinded,
controlled, crossover study. “ Annals
of Internal Medicine 106:497-503
(1987).
Terano, T. "Effect of omega-3
polyunsaturated fatty acid ingestion on
bone metabolsim and osteoporosis."
World Rev Nutr Diet 88:141-=147
(2001).
Volker, Dianne, et al. “Efficacy of fish
oil concentrate in the treatment of
rheumatoid arthritis. “ Journal of
Rheumatology 27:2343-46 (2000).
|
|
Helps
Support Healthy Kidneys
|
|
Brown, S. A., C. A. Brown, W. A.
Crowell, J. A. Barsanti, T. Allen, C.
Cowell, and D. R. Finco. "Beneficial
effects of chronic administration of
dietary omega-3 polyunsaturated fatty
acids in dogs with renal insufficiency."
J Clin Lab Med 131:447-455 (1998).
Brown, S. A., C. A. Brown, W. A.
Crowell, J. A. Barsanti, C-W. Kang, T.
Allen, C. Cowell, and D. R. Finco.
"Effects of dietary polyunsaturated
fatty acids supplementation in early
renal insufficiency in dogs." J Lab
Clin Med 135:275-286 (2000).
Cappelli P., Di Liberato L., Stuard S.,
Ballone E., Albertazzi A. “N-3
polyunsaturated fatty acid
supplementation in chronic progressive
renal disease.” J Nephrol
10(3):157-62 (1997).
Clark, W. F., A Parbtani, C. D. Naylor,
C. M. Levinton, N. Muirhead, E. Spanner,
M. W. Huff, D. J. Philbrick, and B. J.
Holub. "Fish oil in lupus nephritis:
Clinical findings and methodological
implications." Kidney Int
44:75-86 (1993).
Donadio, J. V., E. J. Bergstralh, K. P.
Offord, D. C. Spencer, and D. E. Holley.
"A controlled trial of fish oil in IgA
nephropathy." N Engl J Med
331:1194-1199 (1994).
Donadio, J. V., J. P. Grande, E. J.
Bergstralh, R. A. Dart, T. S. Larson,
and D. C. Spencer. "The long-term
outcome of patients with IgA nephropathy
treated with fish oil in a controlled
trial." J Am Soc Nephrol
10:1772-1777 (1999).
Lenin M., Thiagarajan A., Nagaraj M.,
Varalakshmi P. “Attenuation of
oxalate-induced nephrotoxicity by
eicosapentaenoate-lipoate (EPA-LA)
derivative in experimental rat model.”
Department of Medical Biochemistry,
University of Madras, India.
Pettersson E. E., Rekola S., Berglund
L., Sundqvist K. G., Angelin B.,
Diczfalusy U., Bjorkhem I., Bergstrom J.
“Treatment of IgA nephropathy with
omega-3-polyunsaturated fatty acids: a
prospective, double-blind, randomized
study.” Clin Nephrol 41(4):183-90
(1994).
Prickett, J. D., D. R. Robinson,
and A. D. Steinberg. "Dietary
enrichment with polyunsaturated
acid eicosapentaenoic acid
prevents proteinuria and
prolongs survival in NZBxNZW F1
mice." J Clin Invest
68:556-559 (1981).
Sulikowska B., Manitius J.,
Nieweglowski T.,
Szydlowska-lysiak W., Rutkowski
B. “The effect of therapy with
small doses of mega-3
polyunsaturated fatty acid on
renal reserve and metabolic
disturbances in patients with
primary IGA glomerulopathy.”
Pol Arch Med Wewn
108(2):753-60 (2002).
|
|
Helps
Support Balanced Mood and Sense of Well
Being |
|
Adams. P., S. Lawson, A. Sanigorski, and
A.J. Sinclair. "Arachidonic acid to
eicosapentaenoic acid ratio in blood
correlates positively with clinical
symptoms of depression." Lipids
31:S157-S161 (1996).
Burgress, J. R., L. Stevens, and L.
Peck. "Long-chain polyunsaturated fatty
acids in children with attention-deficit
hyperactivity disorder." Am J Clin
Nutr 71:327S-330S (2000).
Hamazaki, T., S. Sawazaki, M. Itomura,
E. Asaoka, Y. Nagao, N. Nishimura, K.
Yazawa, T. Kuwamori, and M. Kobayashi.
"The effect of docosahexaenoic acid on
aggression in young adults." J Clin
Invest 97:1129-1134 (1996).
Hamazaki, T., S. Sawazaki, M. Itomura,
Y. Nagao, A. Thienprasert, T. Nagasawa,
and S. Watanabe. "Effect of
docosahexaenoic acid on hostility."
World Rev Nutr Diet 88:47-52 (2001).
Hamazaki, T., S. Sawazaki, T. Nagasawa,
Y. Nagao, Y Kanagawa, and K. Yazawa.
"Administration of docosahexaenoic acid
influences behavior and plasma
catecholamine levels at time of
psychological stress." Lipids
34:S33-S37 (1999).
Hamazaki, T., M. Itomura, S. Sawazaki,
and Y. Nagao. "Anti-stress effects of D.
H. A." Biofactors 13:41-45
(2000).
Hamazak T., Thienprasert A., Kheovichai
K., Samuhaseneetoo S., Nagasawa T.,
Watanabe S. “The effect of
docosahexaenoic acid on aggression in
elderly Thai subjects--a
placebo-controlled double-blind study.”
Nutr Neurosc 5(1):37-41 (2002).
Maes, M. "Fatty acid composition in
major depression: Decreased n-3
fractions in cholesterol esters and
increased C20:46/C20:5n3 ratio in
cholester ester and phosopholipds. J
Affect Dis 38:35-46 (1996).
Maes, M., A Christophe, J. Delanghe, C.
Altamura, H. Neels, and H.Y. Meltzer.
"Lowered omega-3 polyunsaturated fatty
acids in serum phospholipids and
cholesterol esters of depressed
patients." Psychiatry Res
85:275-291 (1999).
Mills, D. E., K. M. Prkochin, K. A.
Harvey, and R. P. Ward. "Dietary fatty
acid supplementation alters stress
reactvity and performance in man." J
Human Hypertension 3:111-116 (1989).
Peet, M., J. Brind, C. N. Ramchand, S.
Shah, and G. K. Vankar. "Two
double-blind placebo-controlled pilot
studies of eicosapentaenoic acid in the
treatment of schizophrenia."
Schizophr Res 49:243-251 (2001).
Richardson, A.J., et al. “Red cell and
plasma fatty acid changes accompanying
symptom remission in a patient with
schizophrenia treated with
eicosapentaenoic acid. “ European
Neuropsychopharmacology 10 :189-93
(2000).
Stoll, Andrew L., et al. “Omega 3 fatty
acids in bipolar disorder.” Archives
of General Psychiatry 56:407-12
(1999).
Stoll, A. L., E. Severus, M. P. Freeman,
S. Reuter, H. A. Zhoyan, E. Diamond, K.
K. Cress, and L. B. Marangell. "Omega-3
fatty acids in bipolar depression: A
preliminary double-blind
placebo-controlled trial." Arch Gen
Psychiatry 56:407-412 (1999).
Voigt, R. G., A. M. Llorente, C. L.
Jensen, J. K. Fraley, M.C. Berretta, and
W. C. Heird. "A randomized,
double-blind, placebo-controlled trial
of docosahexaenoic acid supplementation
in children with
attention-deficit/hyperactivity
disorder." J Pediatr 139:189-196
(2001).
Yehuda, S., S. Rabinovitz, R. L. Carasso,
and D. I. Mostofsky. "Essential Fatty
acid preparation improves Alzheimer's
patients' quality of life." Int J
Neurosci 87:141-149 (1996).
|
|
Helps
Support Strength and Stamina |
|
|
Bruckner, G., P. Webb, L. Greenwell, C.
Chow, and D. Richardson. "Fish oil
increases peripheral capillary blood
cell velocity in humans."
Atherosclerosis 66:237-245 (1987).
Muoio, D. M., J. J. Leddy, P. J.
Horvath, A. B. Awad, and D. R.
Pendergast. "Effect of dietary fat on
metabolic adjustments to maximal VO2 and
endurance in runner." Med Sci Sports
Exerc 26:81-88 (1994).
Pendergast, D. R., P. J. Horvath, J. J.
Leddy, and J. T. Venkatraman. "The role
of dietary fat in performance,
metabolism, and health." Am J Sports
Med 24:S53-S58 (1996).
Raastad T., Hostmark A. T., Stromme S.
B. “Omega-3 fatty acid supplementation
does not improve maximal aerobic power,
anaerobic threshold and running
performance in well-trained soccer
players.” Scand J Med Sci Sports
7(1):25-31 (1997).
Salachas, Anastasios, et al. “Effects of
low-dose fish oil concentrate on angina,
exercise tolerance time, serum
triglycerides, and platelet function. “
Angiology 45:1023-31 (1994). |
|
|
|
|
SeaLogix®
Ultra-Refined
Grade Fish Oil Save 20% NOW!
Purchase Fish Oil Online Now or
Call to get Wholesale Pricing
Phone Orders:
1-888-895-9668
(9 AM - 7 PM, EST)
Ingredients:
ultra-refined marine lipid concentrate, lime flavor,
and natural mixed tocopherols.
One teaspoon of liquid SeaLogix®
Fish Oil
contains 2.7 grams of long-chain omega-3 fatty
acids.(1.8 grams of EPA and 0.9 grams of DHA).
Four capsules of SeaLogix®
Fish Oil
contain 2.4
grams of long-chain omega-3 fatty acids (1.6 grams
of EPA and 0.8 grams of DHA).
For comparison purposes, one tablespoon of cod liver
oil contains approximately 2.5 grams of long-chain
omega-3 fatty acids.
Although
this more refined fish oil costs 10-20 times
more than health-food grade, we keep our price per
gram of EPA and DHA as low as possible as shown
below:
|
Type of Fish
Oil
Compare Cost Per Gram |
Price per gram of
EPA & DHA |
| Lowest grade
health-food grade |
$0.30 |
| Molecular
distilled health-food grade |
$0.54 |
SeaLogix®
Ultra Refined Capsules |
$0.56 |
|
SeaLogix® Ultra
Refined Liquid Oil |
$0.49 |
Don't Be
Fooled by the
Price of a Bottle of Fish Oil
Compare SeaLogix® to Other Brands Here!
All fish oils are NOT
created equal!
Scientific
Evidence Reveals a Diet Rich in Long-Chain
Omega-3 Fatty Acids
Helps Support
SeaLogix®
is NOT your grandmother's cod liver oil!
|
|